Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ASC618 in Hemophilia A
NCT04676048Phase 2Recruiting
- Sponsor
- ASC Therapeutics
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ASC618 in hemophilia A, sponsored by ASC Therapeutics. Started Aug 2022; status: recruiting.
02
Drugs
ASC618
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04676048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676048.